What is the recommended management for an adrenal incidentoma that has grown from 1.2mm to 1.4mm over 2 years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Adrenal Incidentaloma with Minimal Growth

For an adrenal incidentaloma that has grown from 1.2mm to 1.4mm over 2 years, no further imaging follow-up or functional testing is required as this represents growth of less than 3mm/year, indicating a benign lesion. 1

Initial Assessment of Adrenal Incidentalomas

  • Most small (<3 cm) incidentally discovered adrenal masses in patients without a history of malignancy are benign, and extensive workup is usually not justified 1
  • The differential diagnosis of adrenal incidentalomas includes benign non-functional adenomas (71-84%), functional adenomas (cortisol-secreting: 1-30%, aldosterone-secreting: 2-7%), pheochromocytomas (1.5-14%), and malignant lesions (adrenocortical carcinoma: 1.2-12%, metastases: 0-21%) 1
  • Initial evaluation should include both imaging characterization and hormonal assessment to determine if the mass is benign or malignant and if it is hormonally active 1

Significance of Growth Rate

  • The American Urological Association guidelines clearly state that no further imaging follow-up or functional testing is required for patients with adrenal lesions that grow <3mm/year on follow-up imaging 1
  • Growth from 1.2mm to 1.4mm over 2 years represents only 0.1mm/year, which is well below the threshold of concern 1
  • Studies have shown that small lipid-rich adrenal incidentalomas typically demonstrate minimal growth (mean 1±2mm over 5 years) and rarely develop hormonal hypersecretion during follow-up 2

Hormonal Evaluation

  • Despite the minimal growth, it's important to note that all patients with adrenal incidentalomas should initially be screened for autonomous cortisol secretion using a 1mg overnight dexamethasone suppression test 3
  • For patients with hypertension and/or hypokalemia, screening for primary aldosteronism with an aldosterone-to-renin ratio is recommended 3
  • Screening for pheochromocytoma is not necessary for lesions with <10 Hounsfield Units (HU) on unenhanced CT and no signs or symptoms of catecholamine excess 1

Follow-up Recommendations

  • Patients with benign non-functional adenomas <4 cm, myelolipomas, and other small masses containing macroscopic fat detected on the initial work-up do not require further follow-up imaging or functional testing 1
  • Adrenalectomy should only be considered for adrenal incidentalomas growing >5 mm/year after repeating a functional work-up 1
  • The growth rate of 0.2mm over 2 years in this case is minimal and not concerning for malignancy 1

Pitfalls to Avoid

  • Avoid unnecessary repeated imaging for small adrenal masses with benign characteristics, as this leads to increased radiation exposure, patient anxiety, and healthcare costs 1
  • Do not perform adrenal mass biopsy routinely for the work-up of an adrenal incidentaloma, as this is rarely indicated and carries risks 1
  • Recognize that most small adrenal incidentalomas are benign adenomas, and the risk of malignant transformation of benign-appearing lesions is 0% to less than 1% 1

In conclusion, the minimal growth of 0.2mm over 2 years in this adrenal incidentaloma is well below the threshold of concern (3mm/year) and does not warrant further imaging or functional testing according to current guidelines.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Laboratory Tests for Adrenal Incidentaloma Follow-up

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.